ライフサイエンスコーパス: Echinacea

1 ntly thought to be nine species in the genus Echinacea.

2 Green tea (29.8% [25 of 84]), echinacea (13.1% [11 of 84]), and essiac (9.5% [8 of 84]

3 The Echinacea alkamides may be assembled from two distinct m

4 ccurred during 7.1% of the URIs treated with echinacea and 2.7% of those treated with placebo (P =.00

5 07 children, including 337 URIs treated with echinacea and 370 with placebo.

6 ll local extirpation in small populations of Echinacea and many other prairie species.

7 ficant differences were detected between the echinacea and placebo groups for any of the measured out

8 stically significant differences between the echinacea and placebo groups.

9 We conducted a 6-y study of 6,357 Echinacea angustifolia (Asteraceae) individuals across 3

10 13 populations of the tallgrass prairie forb Echinacea angustifolia into a prairie restoration and tr

11 e effect of chemically defined extracts from Echinacea angustifolia roots on rhinovirus infection.

12 ngitudinal study of 778 individual plants of Echinacea angustifolia, a widespread perennial species w

13 ticularly on 3 species of purple coneflower (ECHINACEA:) because of the widespread use of purple cone

14 SNPs for any two Echinacea chloroplast genomes ranged from 181 to 910, an

15 rity were not statistically significant with echinacea compared with placebo.

16 ic (Allium sativum), ginkgo (Ginkgo biloba), echinacea (Echinacea purpurea), ginseng (Panax ginseng),

17 Echinacea, ephedra, garlic, ginkgo, ginseng, kava, St Jo

18 BoNT/A zinc metalloprotease inhibitors, from Echinacea, exemplified by the natural product d-chicoric

19 atistically significant effects of the three echinacea extracts on rates of infection or severity of

20 not support the ability of this dose of the echinacea formulation to substantively change the course

21 The Echinacea genus is exemplary of over 30 plant families t

22 supplements (ginkgo biloba, St John's wort, echinacea, ginseng, garlic, saw palmetto, kava kava, and

23 s in the placebo group, and 6.27 days in the echinacea group (between-group difference, -0.52 day [95

24 number of days of peak symptoms (1.60 in the echinacea group and 1.64 in the placebo group; P =.97),

25 =.97), number of days of fever (0.81 in the echinacea group vs 0.64 in the placebo group; P =.09), o

26 and 70 ng/L and 1 cell/hpf in the open-label echinacea group).

27 roup, 58 ng/L and 2 cells/hpf in the blinded echinacea group, and 70 ng/L and 1 cell/hpf in the open-

28 Echinacea groups received the equivalent of 10.2 g of dr

29 llness duration in the blinded and unblinded echinacea groups was 6.34 and 6.76 days, respectively, c

30 as 236 and 258 for the blinded and unblinded echinacea groups, respectively; 264 for the blinded plac

31 Echinacea has been widely used as an herbal remedy for t

32 Other components found in Echinacea, I3 and I4, were also inhibitors of the protea

33 e are few data on the efficacy and safety of echinacea in treating URIs in children.

34 Echinacea is a common botanical used in dietary suppleme

35 Echinacea is a widely used herbal remedy for treatment o

36 th, it is likely that the medicinal value of Echinacea is influenced by cultivation conditions that a

37 Echinacea is widely used to treat the common cold.

38 on different burn schedules, we investigated Echinacea mating scenes, which quantify isolation from p

39 Echinacea may be helpful in the treatment or prevention

40 erennial ornamental plant genera (Agastache, Echinacea, Nepeta, Rudbeckia, and Salvia) revealed varia

41 erence in duration between URIs treated with echinacea or placebo (P =.89).

42 y patients were randomized to receive either echinacea or placebo for up to 3 URIs over a 4-month per

43 95% CI, -69 to 13 points) toward benefit for echinacea (P = 0.089).

44 l groups: no pills, placebo pills (blinded), echinacea pills (blinded), or echinacea pills (unblinded

45 lls (blinded), echinacea pills (blinded), or echinacea pills (unblinded, open-label).

46 Echinacea preparations are widely used to treat the comm

47 Are Echinacea products associated with a reduced incidence a

48 but exploratory meta-analysis suggests that Echinacea products may be associated with a small reduct

49 flicting results, and there are a variety of echinacea products on the market with different phytoche

50 reatment trials, there was no association of Echinacea products with a shorter duration of colds.

51 Compared with placebo, unrefined echinacea provided no detectable benefit or harm in thes

52 Purple coneflower (Echinacea purpurea (L.) Moench) is a popular native Nort

53 An encapsulated mixture of unrefined Echinacea purpurea herb (25%) and root (25%) and E. angu

54 e previously demonstrated that extracts from Echinacea purpurea material varied substantially in thei

55 sativum), ginkgo (Ginkgo biloba), echinacea (Echinacea purpurea), ginseng (Panax ginseng), St John' s

56 Echinacea purpurea, as dosed in this study, was not effe

57 s received the equivalent of 10.2 g of dried echinacea root during the first 24 hours and 5.1 g durin

58 Ethanol extracts from Echinacea roots had potent activity as novel agonists of

59 John's wort, ginseng, echinacea, saw palmetto, and kava.

60 This unusual pathway seems unique to Echinacea species suggesting convergent evolution of chi

61 s not been successful for differentiation of Echinacea species.

62 bioactive compounds and chemical profiles in Echinacea with the goal of improving its human health be

63 Three preparations of echinacea, with distinct phytochemical profiles, were pr